BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 31640747)

  • 1. Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.
    Morgenroth A; Tinkir E; Vogg ATJ; Sankaranarayanan RA; Baazaoui F; Mottaghy FM
    Breast Cancer Res; 2019 Oct; 21(1):116. PubMed ID: 31640747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
    Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
    Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
    Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
    J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Multidose Preparation of a Ready-to-Use
    Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
    Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
    [No Abstract]   [Full Text] [Related]  

  • 5. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Evaluation of
    Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
    Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
    Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
    J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
    J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
    Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
    Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Potential of PSMA as a Vascular Target in TNBC.
    Heesch A; Ortmanns L; Maurer J; Stickeler E; Sahnoun SEM; Mottaghy FM; Morgenroth A
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177).
    Zha Z; Choi SR; Li L; Zhao R; Ploessl K; Yao X; Alexoff D; Zhu L; Kung HF
    J Med Chem; 2022 Oct; 65(19):13001-13012. PubMed ID: 36103652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
    J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of post-therapy
    Tuncel M; Telli T
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing Treatment Efficacy of
    Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [
    Heesch A; Florea A; Maurer J; Habib P; Werth LS; Hansen T; Stickeler E; Sahnoun SEM; Mottaghy FM; Morgenroth A
    Breast Cancer Res; 2024 Feb; 26(1):30. PubMed ID: 38378689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PSMA-targeted radioligand therapy in prostate cancer].
    Heck MM; Retz M; Tauber R; Knorr K; Kratochwil C; Eiber M
    Urologe A; 2017 Jan; 56(1):32-39. PubMed ID: 27885457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR).
    Kryza D; Vinceneux A; Bidaux AS; Garin G; Tatu D; Cropet C; Badel JN; Perol D; Giraudet AL
    BMC Cancer; 2024 Feb; 24(1):163. PubMed ID: 38302933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment.
    Nguyen DP; Xiong PL; Liu H; Pan S; Leconet W; Navarro V; Guo M; Moy J; Kim S; Ramirez-Fort MK; Batra JS; Bander NH
    Mol Cancer Res; 2016 Nov; 14(11):1045-1053. PubMed ID: 27458033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
    Wang S; Blaha C; Santos R; Huynh T; Hayes TR; Beckford-Vera DR; Blecha JE; Hong AS; Fogarty M; Hope TA; Raleigh DR; Wilson DM; Evans MJ; VanBrocklin HF; Ozawa T; Flavell RR
    Mol Pharm; 2019 Sep; 16(9):3831-3841. PubMed ID: 31381351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.